Preclinical pharmacokinetic studies of 3-deazaneplanocin A, a potent epigenetic anticancer agent, and its human pharmacokinetic prediction using GastroPlus™

European Journal of Pharmaceutical Sciences

Volumn 77, Issue , 2015, Pages 290-302

  Sun, Feng ^a   Lee, Lawrence ^a   Zhang, Zhiwei ^a   Wang, Xiaochong ^a   Yu, Qiang ^c   Duan, XiaoQun ^a,b   Chan, Eli ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b GUILIN MEDICAL UNIVERSITY   (China)

^c GENOME INSTITUTE OF SINGAPORE   (Singapore)

Author keywords

3 Deazaneplanocin A; GastroPlu; Human non small cell lung carcinoma; Physiologically based pharmacokinetic models

Indexed keywords

3 DEAZANEPLANOCIN A; ANTINEOPLASTIC AGENT; 3-DEAZANEPLANOCIN; ADENOSINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DOSE RESPONSE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; EPIGENETICS; HUMAN; HUMAN CELL; KINETIC PARAMETERS; LIVER CLEARANCE; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; TISSUE DISTRIBUTION; URINARY EXCRETION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETIC EPIGENESIS; HALF LIFE TIME; NO-OBSERVED-ADVERSE-EFFECT LEVEL; VALIDATION STUDY; WISTAR RAT;

ADENOSINE; ANIMALS; ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; HALF-LIFE; HUMANS; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RATS, WISTAR;

EID: 84938065983     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.06.021     Document Type: Article

References (59)

1. E.P. Acosta, L.M. Page, and C.V. Fletcher Clinical pharmacokinetics of zidovudine. An update Clin. Pharmacokinet. 30 1996 251 262
2. M.R. Blum, S.H. Liao, and P. de Miranda Overview of acyclovir pharmacokinetic disposition in adults and children Am. J. Med. 73 1982 186 192
3. M. Bray, J. Driscoll, and J.W. Huggins Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor Antiviral Res. 45 2000 135 147
4. M.J. Comin, and J.B. Rodriguez First synthesis of (-)-Neplanocin C Tetrahedron 56 2000 4639
5. R.A. Coulombe Jr., R.P. Sharma, and J.W. Huggins Pharmacokinetics of the antiviral agent 3-deazaneplanocin A Eur. J. Drug Metab. Pharmacokinet. 20 1995 197 202
6. B. Davies, and T. Morris Physiological parameters in laboratory animals and humans Pharm. Res. 10 1993 1093 1095
7. S.S. De Buck, V.K. Sinha, L.A. Fenu, R.A. Gilissen, C.E. Mackie, and M.J. Nijsen The prediction of drug metabolism, tissue distribution, and bioavailability of 50 structurally diverse compounds in rat using mechanism-based absorption, distribution, and metabolism prediction tools Drug Metab. Dispos. 35 2007 649 659
8. S.S. De Buck, V.K. Sinha, L.A. Fenu, M.J. Nijsen, C.E. Mackie, and R.A. Gilissen Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs Drug Metab. Dispos. 35 2007 1766 1780
9. G.P. Dobson, and J.H. Cieslar Intracellular, interstitial and plasma spaces in the rat myocardium in vivo J. Mol. Cell. Cardiol. 29 1997 3357 3363
10. C.M. Fillmore, C. Xu, P.T. Desai, J.M. Berry, S.P. Rowbotham, Y.J. Lin, H. Zhang, V.E. Marquez, P.S. Hammerman, K.K. Wong, and C.F. Kim EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors Nature 520 2015 239 242
11. W. Fiskus, Y. Wang, A. Sreekumar, K.M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, R. Balusu, S. Koul, P. Atadja, V.E. Marquez, and K.N. Bhalla Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells Blood 114 2009 2733 2743
12. S. Goel, D.G. Duda, L. Xu, L.L. Munn, Y. Boucher, D. Fukumura, and R.K. Jain Normalization of the vasculature for treatment of cancer and other diseases Physiol. Rev. 91 2011 1071 1121
13. M. Hosseini-Yeganeh, and A.J. McLachlan Physiologically based pharmacokinetic model for terbinafine in rats and humans Antimicrob. Agents Chemother. 46 2002 2219 2228
14. J.B. Houston Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance Biochem. Pharmacol. 47 1994 1469 1479
15. S.W. Hung, H. Mody, S. Marrache, Y.D. Bhutia, F. Davis, J.H. Cho, J. Zastre, S. Dhar, C.K. Chu, and R. Govindarajan Pharmacological reversal of histone methylation presensitizes pancreatic cancer cells to nucleoside drugs: in vitro optimization and novel nanoparticle delivery studies PLoS One 8 2013 e71196
16. S.S. Ibrahim, and F.D. Boudinot Pharmacokinetics of 2',3'-dideoxycytidine after high-dose administration to rats J. Pharm. Sci. 80 1991 36 38
17. T. Iwatsubo, N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C.E. Green, C.A. Tyson, and Y. Sugiyama Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data Pharmacol. Ther. 73 1997 147 171
18. X. Jiang, J. Tan, J. Li, S. Kivimae, X. Yang, L. Zhuang, P.L. Lee, M.T. Chan, L.W. Stanton, E.T. Liu, B.N. Cheyette, and Q. Yu DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications Cancer Cell 13 2008 529 541
19. H.M. Jones, N. Parrott, K. Jorga, and T. Lave A novel strategy for physiologically based predictions of human pharmacokinetics Clin. Pharmacokinet. 45 2006 511 542
20. R. Katayama, N. Yamaguchi, T. Yamashita, S. Watanabe, H. Satoh, N. Yamagishi, and K. Furuhama Calculation of glomerular filtration rate in conscious rats by the use of a bolus injection of iodixanol and a single blood sample J. Pharmacol. Toxicol. Methods 61 2010 59 64
21. J. Kikuchi, T. Takashina, I. Kinoshita, E. Kikuchi, Y. Shimizu, J. Sakakibara-Konishi, S. Oizumi, V.E. Marquez, M. Nishimura, and H. Dosaka-Akita Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells Lung Cancer 78 2012 138 143
22. S.K. Knutson, T.J. Wigle, N.M. Warholic, C.J. Sneeringer, C.J. Allain, C.R. Klaus, J.D. Sacks, A. Raimondi, C.R. Majer, J. Song, M.P. Scott, L. Jin, J.J. Smith, E.J. Olhava, R. Chesworth, M.P. Moyer, V.M. Richon, R.A. Copeland, H. Keilhack, R.M. Pollock, and K.W. Kuntz A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 8 2012 890 896
23. H. Lee, J. Hanes, and K.A. Johnson Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase Biochemistry 42 2003 14711 14719
24. J. Li, S. Zhou, H. Huynh, and E. Chan Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline Pharm. Res. 22 2005 397 404
25. P. Li, T.A. Robertson, Q. Zhang, L.M. Fletcher, D.H. Crawford, M. Weiss, and M.S. Roberts Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage Pharm. Res. 29 2012 1658 1669
26. C.C. Lin, T. Luu, D. Lourenco, L.T. Yeh, and J.Y. Lau Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys J. Antimicrob. Chemother. 51 2003 93 99
27. C.C. Lin, L.T. Yeh, T. Luu, D. Lourenco, and J.Y. Lau Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys Antimicrob. Agents Chemother. 47 2003 1395 1398
28. L. Liu, Z. Xu, L. Zhong, H. Wang, S. Jiang, Q. Long, J. Xu, and J. Guo EZH2 promotes tumor cell migration and invasion via epigenetic repression of E-cadherin in renal cell carcinoma BJU Int. 2014
29. C. Lu, P. Li, R. Gallegos, V. Uttamsingh, C.Q. Xia, G.T. Miwa, S.K. Balani, and L.S. Gan Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: evaluation of free fraction and uptake in hepatocytes Drug Metab. Dispos. 34 2006 1600 1605
30. L.M. Mangravite, I. Badagnani, and K.M. Giacomini Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney Eur. J. Pharmacol. 479 2003 269 281
31. M.T. McCabe, H.M. Ott, G. Ganji, S. Korenchuk, C. Thompson, G.S. Van Aller, Y. Liu, A.P. Graves, A. Della Pietra 3rd, E. Diaz, L.V. LaFrance, M. Mellinger, C. Duquenne, X. Tian, R.G. Kruger, C.F. McHugh, M. Brandt, W.H. Miller, D. Dhanak, S.K. Verma, P.J. Tummino, and C.L. Creasy EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 492 2012 108 112
32. J.G. McHutchison, S.C. Gordon, E.R. Schiff, M.L. Shiffman, W.M. Lee, V.K. Rustgi, Z.D. Goodman, M.H. Ling, S. Cort, and J.K. Albrecht Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group N. Engl. J. Med. 339 1998 1485 1492
33. J.A. Montgomery, S.J. Clayton, H.J. Thomas, W.M. Shannon, G. Arnett, A.J. Bodner, I.K. Kion, G.L. Cantoni, and P.K. Chiang Carbocyclic analogue of 3-deazaadenosine: a novel antiviral agent using S-adenosylhomocysteine hydrolase as a pharmacological target J. Med. Chem. 25 1982 626 629
34. K.M. Morrissey, S.L. Stocker, M.B. Wittwer, L. Xu, and K.M. Giacomini Renal transporters in drug development Ann. Rev. Pharmacol. Toxicol. 53 2013 503 529
35. Y. Naritomi, S. Terashita, S. Kimura, A. Suzuki, A. Kagayama, and Y. Sugiyama Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans Drug Metab. Dispos. 29 2001 1316 1324
36. T. Onodera, and K. Furuhama Determination of inulin and PAH clearance in different types of nephropathy rats Dev. Toxicol. Environ. Sci. 11 1983 443 446
37. C.J. Peer, M. Rao, S.D. Spencer, S. Shahbazi, P.S. Steeg, D.S. Schrump, and W.D. Figg A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 927 2013 142 146
38. M.A. Perazella Drug-induced nephropathy: an update Exp. Opin. Drug Safety 4 2005 689 706
39. P. Poulin, and F.P. Theil Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution J. Pharm. Sci. 91 2002 129 156
40. S. Reagan-Shaw, M. Nihal, and N. Ahmad Dose translation from animal to human studies revisited FASEB J. 22 2008 659 661
41. T. Rodgers, D. Leahy, and M. Rowland Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 94 2005 1259 1276
42. T. Rodgers, and M. Rowland Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 95 2006 1238 1257
43. M. Rowland, C. Peck, and G. Tucker Physiologically-based pharmacokinetics in drug development and regulatory science Ann. Rev. Pharmacol. Toxicol. 51 2011 45 73
44. M. Rowland, and T. Tozer Clinical Pharmacokinetics: Concepts and Applications 1995 Williams & Wilkins London
45. S.W. Schneller Carbocyclic nucleosides (carbanucleosides) as new therapeutic leads Curr. Top. Med. Chem. 2 2002 1087 1092
46. W.R. Sellers, and M. Loda The EZH2 polycomb transcriptional repressor - a marker or mover of metastatic prostate cancer? Cancer Cell 2 2002 349 350
47. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J. Clin. 64 2014 9 29
48. R.A. Star Treatment of acute renal failure Kidney Int. 54 1998 1817 1831
49. F. Sun, E. Chan, Z. Wu, X. Yang, V.E. Marquez, and Q. Yu Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells Mol. Cancer Ther. 8 2009 3191 3202
50. F. Sun, J. Li, Q. Yu, and E. Chan Loading 3-deazaneplanocin A into pegylated unilamellar liposomes by forming transient phenylboronic acid-drug complex and its pharmacokinetic features in Sprague-Dawley rats Eur. J. Pharm. Biopharm. 80 2012 323 331
51. F. Sun, J.C. Ong, Q. Yu, and E. Chan Quantification of 3-deazaneplanocin A, a novel epigenetic anticancer agent, in rat biosamples by hydrophilic interaction liquid chromatography-tandem mass spectrometric detection J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 879 2011 285 290
52. E.K. Tam, T.M. Nguyen, C.Z. Lim, P.L. Lee, Z. Li, X. Jiang, S. Santhanakrishnan, T.W. Tan, Y.L. Goh, S.Y. Wong, H. Yang, E.H. Ong, J. Hill, Q. Yu, and C.L. Chai 3-Deazaneplanocin a and neplanocin a analogues and their effects on apoptotic cell death Chem. Med. Chem. 10 2015 173 182
53. J. Tan, X. Yang, L. Zhuang, X. Jiang, W. Chen, P.L. Lee, R.K. Karuturi, P.B. Tan, E.T. Liu, and Q. Yu Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells Genes Dev. 21 2007 1050 1063
54. H. Tang, A. Hussain, M. Leal, M. Mayersohn, and E. Fluhler Interspecies prediction of human drug clearance based on scaling data from one or two animal species Drug Metab. Dispos. 35 2007 1886 1893
55. K.V. Thrivikraman, R.L. Huot, and P.M. Plotsky Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat Brain Res. Brain Res. Protoc. 10 2002 84 94
56. S. Varambally, S.M. Dhanasekaran, M. Zhou, T.R. Barrette, C. Kumar-Sinha, M.G. Sanda, D. Ghosh, K.J. Pienta, R.G. Sewalt, A.P. Otte, M.A. Rubin, and A.M. Chinnaiyan The polycomb group protein EZH2 is involved in progression of prostate cancer Nature 419 2002 624 629
57. Z.N. Wee, Z. Li, P.L. Lee, S.T. Lee, Y.P. Lim, and Q. Yu EZH2-mediated inactivation of IFN-gamma-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer Cell Rep. 8 2014 204 216
58. J.Z. Wu, G. Larson, H. Walker, J.H. Shim, and Z. Hong Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes Antimicrob. Agents Chemother. 49 2005 2164 2171
59. B. Xia, T. Heimbach, T.H. Lin, H. He, Y. Wang, and E. Tan Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions Cancer Chemother. Pharmacol. 69 2012 1567 1582